Ketamine Therapy for Mental Health: Evidence and Clinical Use

Ketamine therapy occupies a distinct position in psychiatric medicine as the first genuinely novel antidepressant mechanism approved by the U.S. Food and Drug Administration in decades. This page covers the clinical definition and regulatory scope of ketamine use in mental health, its neurobiological mechanism, the diagnostic scenarios in which it is applied, and the boundaries that govern clinical decision-making. The treatment carries both significant therapeutic promise and a documented risk profile that shapes its regulated delivery context.

Definition and scope

Ketamine is a dissociative anesthetic that has been on the U.S. market since 1970 under FDA approval as a general anesthetic (FDA Drug Approval Database, NDA 016812). Its psychiatric application operates under two distinct regulatory frameworks. Racemic ketamine — a 50/50 mixture of its two molecular mirror forms — is administered intravenously as an off-label treatment, meaning its psychiatric use is not specifically FDA-approved but is legally permitted under prescriber authority. Esketamine (the S-enantiomer of ketamine), marketed as Spravato, received FDA approval in March 2019 specifically for treatment-resistant depression and, in August 2020, for major depressive disorder with acute suicidal ideation or behavior (FDA Spravato Prescribing Information, NDA 211243).

Spravato is a Schedule III controlled substance under the Controlled Substances Act (21 U.S.C. § 812), administered as a nasal spray exclusively in certified healthcare settings under a Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA. Racemic IV ketamine carries no equivalent federal REMS requirement, though individual states may impose additional oversight through their respective pharmacy and medical practice boards.

The American Psychiatric Association published a consensus statement in 2017 acknowledging the clinical use of ketamine for depression while noting the absence of long-term safety data at that time (APA Council on Research Task Force on Novel Biomarkers and Treatments).

How it works

Unlike conventional antidepressants — which primarily modulate monoamine neurotransmitters such as serotonin, norepinephrine, or dopamine — ketamine acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor subtype. Glutamate is the brain's primary excitatory neurotransmitter, and NMDA receptor blockade triggers a downstream cascade that rapidly increases synaptic availability of glutamate in targeted circuits.

This mechanism produces two clinically relevant effects:

  1. Rapid symptom onset: Antidepressant effects can emerge within hours to days of administration, compared to the 2–6 week onset typical of selective serotonin reuptake inhibitors (SSRIs). This speed is particularly relevant in acute suicidality contexts.
  2. Synaptogenesis: Research published in Science (Li et al., 2010) identified that ketamine promotes the rapid growth of synaptic connections in prefrontal cortical neurons in animal models, a finding that has informed mechanistic hypotheses in human research.
  3. AMPA receptor potentiation: Glutamate released by NMDA blockade activates AMPA receptors, which triggers brain-derived neurotrophic factor (BDNF) signaling — a pathway implicated in neuroplasticity and antidepressant response.
  4. Dissociative and perceptual effects: Ketamine produces dose-dependent dissociation, derealization, and perceptual distortion during infusion. These effects are transient but require monitored clinical settings.

The National Institute of Mental Health (NIMH) has funded and summarized research on glutamate-based interventions, identifying the NMDA pathway as a primary target for next-generation treatment development (NIMH Research on Depression).

Common scenarios

Ketamine therapy is applied in a structured set of diagnostic contexts, not as a first-line intervention. Clinical use concentrates in conditions where standard treatments have failed or where rapid response is medically necessary. The depression and mood disorders reference covers the diagnostic criteria underpinning most ketamine indications.

Treatment-resistant depression (TRD) is the most established indication. TRD is conventionally defined as failure to respond adequately to at least 2 antidepressant trials of adequate dose and duration (FDA Spravato label, §1.1). Esketamine (Spravato) holds its primary approval for this population.

Major depressive disorder with acute suicidal ideation or behavior (MDSI) represents the second FDA-approved indication for esketamine. This application targets the clinical gap in acute crisis settings, where the delay inherent to conventional pharmacotherapy creates measurable risk. The suicidality and crisis intervention reference addresses the broader crisis framework within which this indication operates.

Bipolar depression and post-traumatic stress disorder represent areas of active investigation without primary FDA approval for ketamine. PTSD and trauma-related disorders involves overlapping neurobiological pathways — glutamatergic dysregulation has been identified in PTSD research — and early-phase trials have examined ketamine in this population. Findings have not yet produced regulatory approval for this use.

Comparator context — ECT vs. ketamine: Electroconvulsive therapy (ECT) remains the most robustly evidence-supported intervention for severe, treatment-resistant depression. ECT produces response rates documented at 60–80% in eligible populations (American Journal of Psychiatry, multiple meta-analyses). Ketamine's response durability is shorter without maintenance protocols, but its non-invasive delivery and rapid onset distinguish it procedurally from ECT.

Decision boundaries

Clinicians and institutions operating within ketamine programs navigate a defined set of contraindications, monitoring requirements, and treatment boundaries established by prescribing guidelines and the FDA REMS program.

Absolute contraindications identified in FDA labeling for esketamine include:

Relative contraindications and risk categories requiring clinical judgment include uncontrolled hypertension, active psychosis, and history of dissociative disorders. The FDA REMS for Spravato requires that all doses be administered and that patients be observed for at least 2 hours post-dose in a certified healthcare setting due to risks of sedation, dissociation, and blood pressure elevation (Spravato REMS Program).

The FDA REMS also prohibits dispensing Spravato for home use. This represents a hard structural boundary distinguishing esketamine from most oral psychiatric medications. Racemic IV ketamine infusion clinics operate outside this REMS but are subject to state-level controlled substance regulations and DEA registration requirements under 21 C.F.R. Part 1301, as amended effective February 5, 2026. Practitioners should consult the current amended text of 21 C.F.R. Part 1301 for updated registration, recordkeeping, and security requirements applicable to Schedule III controlled substances, including ketamine, as those provisions govern clinic-level DEA compliance following the February 5, 2026 effective date.

Psychiatric medication classes provides the broader pharmacological reference taxonomy within which ketamine sits as a dissociative/glutamatergic agent — separate from the four major conventional classes (antidepressants, antipsychotics, mood stabilizers, and anxiolytics).

Substance use disorder history is a documented clinical consideration given ketamine's Schedule III status and established potential for misuse. Substance use disorders and co-occurring mental health conditions must be assessed before initiating treatment. The DEA classifies ketamine as having moderate-to-low physical dependence potential and moderate psychological dependence potential, consistent with Schedule III placement.

Treatment course structure for IV racemic ketamine typically follows a 6-infusion induction series administered over 2–3 weeks, with maintenance infusions thereafter as clinically indicated. This structure is not federally mandated but reflects the protocol used in the largest published clinical studies. Esketamine labeling specifies an induction phase of twice-weekly dosing for 4 weeks, followed by weekly and then biweekly maintenance, with dose options of 56 mg or 84 mg per session.

References

📜 3 regulatory citations referenced  ·  ✅ Citations verified Feb 25, 2026  ·  View update log

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Bmi Health Metrics Calculator